Tempest Therapeutics' Stock Skyrockets with Promising Liver Cancer Treatment
Tempest Therapeutics (TPST) stock is up 325% as the clinical-stage oncology company prepares to release updated study results from a Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab as a first-line treatment for hepatocellular carcinoma. Investors are eagerly awaiting the results, with heavy trading volume indicating high expectations. If the study fails to deliver positive news, TPST stock may lose the momentum it has gained.